C12N2533/76

Three-dimensional printed organs, devices, and matrices

Provided herein are methods and systems for bio-printing of three-dimensional organs and organoids. Also provided herein are bio-printed three-dimensional organs and organoids for use in the generation and/or the assessment of immunological products and/or immune responses. Also provided herein are methods and system for bio-printing three-dimensional matrices.

Engineering Of Innervated Tissue And Modulation Of Peripheral Organ Activity
20220010269 · 2022-01-13 ·

In various aspects and embodiments, the present invention provides methods for preparing innervated tissue. In various embodiments the invention further provides innervated tissue generated using the methods described herein. In various embodiments the inclusion of optogenetically transducible TENGs or Micro-TENNs in the innervated tissue allows the modulation of tissue or organs by using light to stimulate the optogenetically transducible TENGs or Micro-TENNs.

Method for predicting and monitoring clinical response to immunomodulatory therapy

The present invention provides a method to quantitatively measure the response of a patient to an immune-modulator drug that will aid clinicians in the determination of the optimal combination/posology of immunosuppressant/immune-modulator drugs. In addition, this method will open the possibility for clinicians to make the necessary adjustments in immunosuppressive therapy, as a way to avoid organ rejection to actually take place. Furthermore, this method will significantly reduce side effects of immunosuppressant drugs, optimizing therapeutic scheme and dosages, enabling the determination of the most effective immunosuppression regimen at the lower dosages for each patient individually and monitoring of treatment efficiency along time, thus opening the door to treatment personalization.

METHOD FOR INDUCING AND DIFFERENTIATING PLURIPOTENT STEM CELLS AND USES THEREOF

The present invention refers to a method for inducing pluripotent stem cells starting from somatic cells isolated from healthy and/or diseased individuals. The diseased individual is preferably affected by a genetic disease such as type A hemophilia, and the somatic cells from the diseased individual are genetically corrected for the mutation causing the disease preferably after being reprogrammed by the method of the present invention. A further aspect of the present invention refers to a method for differentiating induced pluripotent stem cells or embryonic stem cell-like into endothelial cells. Moreover, the present invention refers to the use of these cells as a medicament for treating a disease, in particular, a genetic disease such as type A hemophilia.

Multilayered Vascular Tubes
20230320837 · 2023-10-12 ·

Described herein are engineered multilayered vascular tubes comprising at least one layer of differentiated adult fibroblasts, at least one layer of differentiated adult smooth muscle cells, wherein any layer further comprises differentiated adult endothelial cells, wherein said tubes have the following features: (a) a ratio of endothelial cells to smooth muscle cells of about 1:99 to about 45:55; (b) the tube is compliant; (c) the internal diameter of the tube is about 6 mm or smaller; (d) the length of the tube is up to about 30 cm; and (e) the thickness of the tube is substantially uniform along a region of the tube; provided that the engineered multilayered vascular tube is free of any pre-formed scaffold. Also described herein are methods of forming said tubes and uses for said tubes including methods for treating patients, comprising providing such a tube into to a patient in need thereof.

Cell culturing structure including growth medium and non-growth medium

A structure for culturing cells includes growth medium regions on a surface of the structure. Each of the growth medium regions includes a growth medium surface configured to receive and promote growth in a cell that is being cultured. The structure includes a non-growth medium. The non-growth medium includes a non-growth medium surface configured to receive the cell that is being cultured.

Biomimetic support for three-dimensional cell culturing, method for manufacturing same, and use thereof

Disclosed is a method for manufacturing a composite nanofiber support and a fish collagen/synthetic polymer nanofiber support manufactured by the method, wherein the method comprises: a first step for dissolving a synthetic polymer in an organic solvent; a second step for dissolving a fish collagen in water to prepare an aqueous fish collagen solution; a third step for adding the aqueous fish collagen solution prepared in the second step to the synthetic polymer solution prepared in the first step, followed by mixing; and a fourth step for electrospinning the mixture solution prepared in the third step to manufacture a nanofiber support.

MULTIFUNCTIONAL IMMATURE DENTAL PULP STEM CELLS AND THERAPEUTIC APPLICATIONS
20230313143 · 2023-10-05 ·

The present invention is directed to therapeutic multifunctional immature dental pulp stem cells (IDPSCs), and IDPSCs multi-lineage compositions. The invention is further directed to the use of IDPSCs and compositions to reduce the risk of and/or treat degenerative diseases or for other medicinal and aesthetic purposes.

QUANTIFYING CELL-DERIVED CHANGES IN COLLAGEN SYNTHESIS, ALIGNMENT, AND MECHANICS IN A 3D CONNECTIVE TISSUE MODEL
20230279356 · 2023-09-07 ·

Described herein are in vitro quantitative methods directed to 3D extracellular matrix (ECM) organization and mechanics. The methods do not require application of an external force, anchorage, or a scaffolding material in order to culture ECM tissue constructs, and the methods enable quantitative measurements without crosstalk noise from variables attributable to external forces, anchorage, and scaffolding material.

EXTRACELLULAR MATRICES WHICH CAN BE USED AS SCAFFOLD FOR LIVING CELLS

The present invention discloses an extracellular matrix comprising a modified polysaccharide consisting of repeating disaccharide units whereby in at least 11% of the disaccharide units one primary alcohol group is oxidized into a carboxylic acid.